John Mutkoski, a partner in Goodwin’s Corporate, Technology and Life Sciences groups, concentrates in general corporate and securities law and has significant experience in public offerings (representing issuers and underwriters), venture capital and corporate finance, mergers and acquisitions, SEC compliance, corporate governance, and technology licensing and joint ventures.

Mr. Mutkoski is Co-Chair of Goodwin’s PropTech Initiative, which is focused on supporting the intersection of Real Estate and Technology through thoughtful collaboration across the two practice areas. Mr. Mutkoski’s keen understanding of the importance of connecting real estate and technology clients, paired with his collaborative nature, allows for even more natural synergy between these two practices. Mr. Mutkoski’s select clients in the PropTech industry include RXR Realty, Building Footprint, Iconics, Monetics and Coyote Labs.

Mr. Mutkoski is a key contributor to Goodwin’s Founders Workbench, an online resource for start-ups, emerging companies and the entrepreneurial community.

Areas of Practice
Domaines D’Expertise





Mr. Mutkoski represents publicly and privately held corporations in a variety of industries including software, hardware, life sciences, communications, education and information technology services. He also represents investment banks, private equity firms and venture capital funds in connection with private investments and public offerings in those industries.

Publicly held companies represented by Mr. Mutkoski have included Monotype Imaging Holdings Inc., Concert Pharmaceuticals, Inc., Akero Therapeutics, Inc., Casa Systems, CIFC Corp., Phase Forward Incorporated, Albany Molecular Research, Inc., The Princeton Review, Inc., Candela Corporation, Animal Health International, Inc., Metabolix, Inc., Proteostasis Therapeutics, Inc. and Concerto Software, Inc. (formerly Davox Corporation).

Representative Matters



Capital Markets
  • Nerdy in its business combination with TPG Pace Tech Opportunities
  • Ablynx NV, Akero Therapeutics, Animal Health International, Metabolix, Phase Forward and Proteostasis Therapeutics in their initial public offerings
  • Akero Therapeutics in its $230 and $216 million registered follow-on offerings
  • Concert Pharmaceuticals in its $74 million registered follow-on offering and ATM facility
  • Proteostasis Therapeutics in its $40 and $65 million registered follow-on offerings
  • Metabolix in several registered follow-on offerings
Mergers and Acquisitions
  • Nerdy in its business combination with TPG Pace Tech Opportunities
  • Monetics in its sale to Derivative Path
  • Hawkins Point in its sale to Verista
  • Building Footprint in its sale to Lightbox
  • TriNetX in its sale to The Carlyle Group
  • Monotype in its sale to HGGC
  • Monotype in its acquisitions of Hoefler&Co, Bitstream, Ascender, Fontcommerce, Design by Front, PlanetWeb, Mark Boulton Design and TextPride, and in the sale of its former subsidiary, Olapic to Social Native
  • Hemera Biosciences in its sale to Janssen
  • Veracode in its acquisition of Hunter2
  • Concert Pharmaceuticals in its sale of its cystic fibrosis assets, CTP-656, to Vertex Pharmaceuticals
  • Iconics in its sale to Mitsubishi Electric Corporation
  • Sun Life Financial in its acquisition of DailyFeats
  • Albany Molecular Research in its acquisitions of Whitehouse Labs and Aptuit
  • The Princeton Review in its acquisitions of Penn Foster Education Group and numerous other companies, and the sale of its K-12 division to Core Education and its Test Prep division to Charlesbank
  • Candela Corporation in its merger with Syneron Medical Ltd.
  • HealthMedia in its sale to Johnson & Johnson
  • BlueTarp Financial in its sale to Capital One
  • Virtustream in its sale to EMC Corporation
  • Direct Hit in its sale to Ask Jeeves
  • Numara Software in its acquisitions of Unipress Software and Criston Software
  • ·netNumina in its sale to Keane
  • Concerto Software in its acquisitions of Cellit and Answersoft and its merger with Melita International
  • Performable in its sale to HubSpot
  • PhaseForward in its merger with Oracle and its acquisitions of Maaguzi, Waban Software, Clarix, Clinsoft, Lincoln Technologies and Green Mountain Logic
  • SingleHop in its sale to Internap Corporation
Venture Financings

Recently completed venture financings on behalf of his corporate clients include investments in:

  • Moderna in its $450 and $500 million preferred stock financings
  • TriNetX in its $40 million Series D financing
  • Varsity Tutors in its financings
  • Federated Wireless in its $42 million Series B financing
  • Virtustream in its $40 million Series D financing
  • Akero in its $45.5 million Series B financing
Professional Experience

Prior to joining Goodwin in 2005, Mr. Mutkoski was a partner in the Business Practice Group at Testa, Hurwitz & Thibeault in Boston.


Mr. Mutkoski has been recognized by The Best Lawyers in America Best Lawyers for his work in Corporate Law from 2007 through 2023.

Mr. Mutkoski has been recognized as a “Massachusetts Super Lawyer” as published in Boston magazine. He has also been selected for inclusion in Best Lawyers.

In 2014, Mr. Mutkoski was Lexology’s Client Choice Awards exclusive winner of the General Corporate category for Massachusetts.

In The News









J.D., 1988
Cornell Law School
B.A., 1985
Boston University

(magna cum laude)



Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique